Armis Recognized for Innovation; Named to Inc. Best in Business List for the Second Consecutive Year
Annual list spotlights companies and leaders delivering meaningful results for their industries, customers and future growth
Armis, the cyber exposure management & security company, today announced that it has once again been named to Inc.’s Best in Business list, specifically highlighted in the Best in Innovation category for 2025. Inc.’s annual Best in Business Awards celebrate the exceptional achievements and contributions of companies that have made a profound impact on their industries and on society at large.
“Armis rapidly innovates and continuously enhances our comprehensive Cyber Exposure Management Platform so that global organizations can proactively protect against cyber threats before there’s any impact,” said Yevgeny Dibrov, CEO and Co-Founder of Armis. “Unlike other solutions on the market, Armis addresses the entire lifecycle of managing cyber threats so that security teams no longer reactively respond to breaches. This is a strategic and monumental shift for the industry to stay a step ahead of threat actors and hugely beneficial to keeping society as we know it safe from disruptions.”
Since being recognized on this list in 2024, Armis has continuously enhanced its already robust product capabilities and expanded its ability to reach new market segments in need of its solutions. Armis launched Armis Federal, a dedicated division to support the unique cybersecurity challenges of U.S. government entities, and completed its third acquisition in 12 months to fuel further product innovation. In the past year, Armis has also expanded its partner ecosystem, deepening integrations with NVIDIA and Fortinet.
Additionally, Armis has received a number of accolades for its Cyber Exposure Management Platform, Armis Centrix™. For its platform impact, Armis was named a Leader in The Forrester Wave™: IoT Security Solutions, Q3 2025, on the heels of its recognition in The Forrester Wave™: Unified Vulnerability Management Solutions, Q3 2025. Both evaluations followed Armis being named a Leader in the Gartner® Magic Quadrant™ for CPS Protection Platforms earlier this year.
Armis recently completed a pre-IPO funding round of $435 million, bringing the company’s valuation to $6.1 billion. The investment round comes amid Armis’ rapid growth and will support continued product innovation, go-to-market expansion and strategic acquisitions to benefit Armis customers, including over 40% of the Fortune 100 and 7 of the Fortune 10.
This recognition honors companies that, through exceptional execution, have achieved significant milestones and core business wins, like customer expansion, key product launches, increased market share, and industry-defining accomplishments. Companies from a wide range of industries – such as technology, health care, finance, and retail – have been recognized for their success and their positive influence on the business world.
Read additional information about Inc.’s 2025 Best in Business list here.
Learn more about Armis Centrix™ and each of the solutions offered by Armis here.
About Armis
Armis, the cyber exposure management & security company, protects the entire attack surface and manages the organization’s cyber risk exposure in real time. In a rapidly evolving, perimeter-less world Armis ensures that organizations continuously see, protect and manage all critical assets – from the ground to the cloud. Armis secures Fortune 100, 200 and 500 companies as well as national governments, state and local entities to help keep critical infrastructure, economies and society stay safe and secure 24/7. Armis is a privately held company headquartered in California.
View source version on businesswire.com: https://www.businesswire.com/news/home/20251202375703/en/
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Aurigene Oncology Limited Announces Encouraging Initial Data From 1st Two Cohorts of Phase 1 Study of AUR112, an Oral Small Molecule Inhibitor of MALT1, in Relapsed/Refractory Lymphoid Malignancies2.12.2025 14:00:00 CET | Press release
Aurigene Oncology Limited, a clinical-stage biopharmaceutical company developing novel therapies in oncology,today announced initial clinical results from 1st two cohorts of its ongoing Phase 1 clinical trial evaluating AUR112 in patients with relapsed or refractory lymphoid malignancies. Early findings show that AUR112 is safe, well tolerated, demonstrating meaningful clinical activity, with objective responses observed across multiple lymphoma subtypes, including Mantle Cell Lymphoma (MCL) and Marginal Zone Lymphoma (MZL). “We are very encouraged by the early results of the first two cohorts from our Phase 1 study of AUR112,” said Dr. Murali Ramachandra, CEO. “AUR112 has shown a promising initial clinical profile, achieving an overall response rate of 63.6% in the efficacy-evaluable population and 58.3% in the intent-to-treat group. These strong early data, combined with its distinct preclinical and safety characteristics, reinforce our belief that AUR112 has the potential to become
AdvanCell Initiates Phase 2 Expansion Trial of ADVC001, a Novel Targeted Alpha Therapy for Prostate Cancer2.12.2025 14:00:00 CET | Press release
Clinical development of 212Pb-ADVC001 (ADVC001) is advancing rapidly with encouraging Phase 1b data presented at ESMO 2025 The Phase 2 expansion will evaluate 160 MBq and 200 MBq doses of ADVC001 using a randomized, multi-dose-response design and adaptive dosing strategies to optimize clinical outcomes across three indications: metastatic hormone-sensitive prostate cancer (mHSPC) and metastatic castration-resistant prostate cancer (mCRPC) in pre-chemotherapy and post-177Lu-PSMA radioligand therapy (RLT) settings AdvanCell, a clinical-stage radiopharmaceutical company developing innovative targeted alpha therapies for cancer, today announced the initiation of the TheraPb Phase 2 expansion trial (NCT05720130) evaluating its lead investigational candidate, ADVC001, in metastatic prostate cancer. The news follows the encouraging Phase 1b dose escalation results presented at the European Society for Medical Oncology (ESMO) 2025 congress that showed a favorable safety profile and compelling
Luma AI Opens for International Business With Former WPP Executive Jason Day Leading New London Office2.12.2025 14:00:00 CET | Press release
Establishment of the London office follows Luma AI’s $900 million Series C investment led by HUMAIN - marking the company’s first major step towards international scale with plans to deepen partnerships across the UK, European Union, and Saudi Arabia in the first phase of expansion.Former Monks and WPP executive Jason Day was appointed Head of EMEA to launch Luma AI internationally and drive worldwide growth across creative, advertising, gaming, and entertainment sectors.Luma AI plans to add 200 new jobs in London in 2026. Luma AI, the frontier artificial intelligence company building multimodal AGI intelligence and known for its flagship product Dream Machine, today announced a major step in its global expansion with the opening of its first international office in London, UK. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251202217704/en/ LUMA AI OPENS FOR INTERNATIONAL BUSINESS WITH FORMER WPP EXECUTIVE JASON DAY LEADING
Eventbrite Enters into Definitive Agreement to Be Acquired by Bending Spoons for Roughly $500 Million to Accelerate Eventbrite’s Next Phase of Growth2.12.2025 13:30:00 CET | Press release
Eventbrite stockholders to receive $4.50 per share in cash Eventbrite, Inc. (NYSE: EB), the leading global marketplace for shared experiences, announced today that it has entered into a definitive agreement to be acquired by Bending Spoons, in an all-cash transaction valued at approximately $500 million. The acquisition is subject to customary closing conditions and approvals, including regulatory approvals and approval by Eventbrite’s stockholders. “For two decades, Eventbrite has stood at the forefront of the experience economy, helping tens of millions to create, discover, and attend unforgettable events,” said Luca Ferrari, Bending Spoons CEO and Co-Founder. “Joining forces with Bending Spoons will accelerate innovation and strengthen Eventbrite’s tools and resources to bring even more people together through shared live experiences for many years to come. As longstanding fans, we’ve identified a few opportunities that we’re excited about exploring with the Eventbrite team after cl
Egle Therapeutics Initiates Phase 1 Healthy Volunteer Study of EGL-003, a Next Generation Treg IL-2 Agonist for Atopic Dermatitis2.12.2025 12:32:00 CET | Press release
Egle Therapeutics SAS (Egle), a clinical-stage biotechnology company developing precision medicines that modulate regulatory T cells (Tregs) to restore immune balance, today announced dosing of the first healthy volunteer in the Phase 1 clinical study of EGL-003, an IL‑2⍺-biased mutein designed to selectively activate Tregs while limiting effector T cell stimulation, as a potential treatment for atopic dermatitis. The open-label, multi-center Phase 1 trial begins with a single ascending dose portion in healthy volunteers to rapidly generate foundational safety, pharmacokinetic (PK), and pharmacodynamic (PD) data. These findings will inform dose selection and scheduling for the subsequent multiple ascending dose portion in approximately 40 adults with atopic dermatitis (AD), which will evaluate safety, PK/PD, and early clinical activity versus placebo. Data from both study segments are expected to guide dose selection for a planned Phase 2a trial in AD aimed at establishing clinical pro
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom